OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Recruiting

Phase 2

OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer

Sponsor:

Mridula George, MD

Code:

NCT05949021

Conditions

Triple Negative Breast Cancer (TNBC)

Eligibility Criteria

Sex: Female

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Combination of liposomal doxorubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Mridula George, MD on 2025-04-27.